www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Amphion investee WellGen recognized as nutraceutical innovator by Global Business Insights
IP commercialisation company Amphion Innovations (AIM: AMP) has announced that its investee company WellGen Inc was recognised as an innovator in Global Business Insights’ newly released report “Key Players and Innovative Start-Ups in Nutraceuticals,” which analysed companies engaged in commercialising nutraceuticals including household names like Nestle, Danone, Abbott, DSM and Provexis.
The report by Business Insights, which is one of the major providers of strategic analysis of innovation in health and wellness, described the WellGen business model and WellGen’s first medical product, a theaflavin rich black tea concentrate (WG0401) the following way: (WG0401) is an anti-inflammatory agent that, among other effects, decreases expression of cyclooxygenase-2 (COX-2). COX-2 was the target of multi-billion dollar pharma compounds such as Vioxx, which has been withdrawn from the market for safety reasons. In contrast to Vioxx, WG0401 modulates a number of pro- and anti-inflammatory genes essential to help the body respond to and recover from inflammatory challenges such as intense exercise or illness.”
Medical foods were identified as a potential growth area for the future for reasons including the advancement of medical food technology, providing better tasting and better texture medical foods, opportunities to expand the consumer base of a medical food based on benefits that are relevant to other populations and advances in science, that will continue linking more diseases to diet and nutrition.
“We are delighted that WG has been recognized as an innovator by strategic market experts. We are determined to bring value to consumers, health care professionals, and our investors by employing our technology to discover and develop safe medical food products that address major inflammatory diseases,” said Chief Executive of WellGen Roddy Carter.
The pharma-like research conducted innovative players like WellGen demonstrated the value of their medical foods and products, enabling them to publicize more of the research to establish the nature of the effect of the nutraceutical in treating, preventing or curing a disease state, said the report.
The industry is projected to take off once a few such companies achieve success by applying this model, turning them into attractive acquisition targets or possibly significant strategic players offering licensing opportunities for the largest food and ingredients companies in near future.
Amphion holds a 14.6% stake in WellGen. Its other investments include Firestar Software (15.3%), Axcess International (8.5%), Motif Biosciences (38.5%), MSA Holdings B.S.C. (50%), M2M Imaging Corp (24.4%), Myconostica (22%), Private Markets (25%), Kromek (19.99%) and DataTern (100%).
